{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:44Z","timestamp":1792783484270,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","id":[{"id":"https:\/\/ror.org\/001nxvg84","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01033-8","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:52:47Z","timestamp":1789494767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Preferences of Physicians of Pediatric Patients with Attention-Deficit\/Hyperactivity Disorder in the United States and Canada: A Discrete Choice Experiment"],"prefix":"10.1007","author":[{"given":"Jeff","family":"Schein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9439-595X","authenticated-orcid":false,"given":"Marjolaine","family":"Gauthier-Loiselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryaline","family":"Catillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Libchaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Cloutier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Childress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"4","key":"1033_CR1","doi-asserted-by":"publisher","first-page":"e20192528","DOI":"10.1542\/peds.2019-2528","volume":"144","author":"ML Wolraich","year":"2019","unstructured":"Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528.","journal-title":"Pediatrics"},{"key":"1033_CR2","unstructured":"CADDRA - Canadian ADHD resource alliance: Canadian ADHD practice guidelines, 4.1 Edition. Toronto, ON; CADDRA, 2020."},{"key":"1033_CR3","doi-asserted-by":"publisher","first-page":"1343314","DOI":"10.3389\/fpsyt.2024.1343314","volume":"15","author":"B French","year":"2024","unstructured":"French B, Nalbant G, Wright H, et al. The impacts associated with having ADHD: an umbrella review. Front Psychiatry. 2024;15:1343314.","journal-title":"Front Psychiatry"},{"issue":"3","key":"1033_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/15374416.2024.2335625","volume":"53","author":"ML Danielson","year":"2022","unstructured":"Danielson ML, Claussen AH, Bitsko RH, et al. ADHD prevalence among U.S. children and adolescents in 2022: diagnosis, severity, co-occurring disorders, and treatment. J Clin Child Adolesc Psychol. 2022;53(3):343\u201360.","journal-title":"J Clin Child Adolesc Psychol"},{"key":"1033_CR5","unstructured":"Child and Adolescent Health Measurement Initiative. 2023 National Survey of Children\u2019s Health (NSCH) data query. Data Resource Center for Child and Adolescent Health supported by the U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA), Maternal and Child Health Bureau (MCHB). https:\/\/www.childhealthdata.org. Accessed July 23, 2025."},{"key":"1033_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12081051","author":"SD Espinet","year":"2022","unstructured":"Espinet SD, Graziosi G, Toplak ME, et al. A review of Canadian diagnosed ADHD prevalence and incidence estimates published in the past decade. Brain Sci. 2022. https:\/\/doi.org\/10.3390\/brainsci12081051.","journal-title":"Brain Sci"},{"key":"1033_CR7","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-1682","author":"ML Wolraich","year":"2019","unstructured":"Wolraich ML, Chan E, Froehlich T, et al. ADHD diagnosis and treatment guidelines: a historical perspective. Pediatrics. 2019. https:\/\/doi.org\/10.1542\/peds.2019-1682.","journal-title":"Pediatrics"},{"issue":"3","key":"1033_CR8","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41380-018-0116-3","volume":"24","author":"A Caye","year":"2019","unstructured":"Caye A, Swanson JM, Coghill D, et al. Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Mol Psychiatry. 2019;24(3):390\u2013408.","journal-title":"Mol Psychiatry"},{"key":"1033_CR9","unstructured":"Vyvanse (lisdexamfetamine dimesylate) prescribing information. Lexington, MA: Takeda Pharmaceuticals America, Inc. http:\/\/pi.shirecontent.com\/PI\/PDFs\/Vyvanse_USA_ENG.pdf. Accessed July 24, 2025."},{"key":"1033_CR10","unstructured":"Concerta (methylphenidate HCl) extended-release tablets CII prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/CONCERTA-pi.pdf. Accessed July 24, 2025."},{"key":"1033_CR11","unstructured":"Jornay PM (methylphenidate hydrochloride) extended-release capsules prescribing information. Morrisville, NC: Ironshore Pharmaceuticals Inc. https:\/\/www.collegiumpharma.com\/wp-content\/uploads\/JORNAY_PM_Label.pdf. Accessed July 24, 2025."},{"key":"1033_CR12","unstructured":"Strattera (atomoxetine) prescribing information. Indianapolis, IN: Lilly USA, LLC. https:\/\/uspl.lilly.com\/strattera\/strattera.html#pi. Accessed July 24, 2025."},{"key":"1033_CR13","unstructured":"Qelbree (viloxazine extended-release capsules) prescribing information. Rockville, MD: Supernus Pharmaceuticals, Inc. https:\/\/www.supernus.com\/sites\/default\/files\/Qelbree-Prescribing-Info.pdf. Accessed July 24, 2025."},{"key":"1033_CR14","unstructured":"Intuniv (guanfacine) prescribing information. Wayne, PA: Shire US Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022037s009lbl.pdf. Accessed July 24, 2025."},{"key":"1033_CR15","unstructured":"NCT05428033. A trial of centanafadine efficacy and safety in children with attention-deficit\/hyperactivity disorder (ADHD): ClinicalTrials.gov; [updated July 22, 2025]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05428033?intr=NCT05428033&rank=1. Accessed July 24, 2025."},{"key":"1033_CR16","unstructured":"NCT05257265. A trial of centanafadine efficacy and safety in adolescents with attention-deficit\/hyperactivity disorder [updated September 27, 2024]. https:\/\/clinicaltrials.gov\/study\/NCT05257265?intr=NCT05257265&rank=1. Accessed July 24, 2025."},{"issue":"9","key":"1033_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727\u201338.","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"1033_CR18","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cpr.2014.06.002","volume":"34","author":"O Lindhiem","year":"2014","unstructured":"Lindhiem O, Bennett CB, Trentacosta CJ, et al. Client preferences affect treatment satisfaction, completion, and clinical outcome: a meta-analysis. Clin Psychol Rev. 2014;34(6):506\u201317.","journal-title":"Clin Psychol Rev"},{"issue":"6","key":"1033_CR19","doi-asserted-by":"publisher","first-page":"S310","DOI":"10.1016\/j.jval.2024.03.1957","volume":"27","author":"J Schein","year":"2024","unstructured":"Schein J, Cloutier M, Gauthier-Loiselle M, et al. Treatment preferences of adult patients with attention-deficit\/hyperactivity disorder in Canada: a discrete choice experiment. Value Health. 2024;27(6):S310.","journal-title":"Value Health."},{"key":"1033_CR20","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2147\/PPA.S467724","volume":"18","author":"J Schein","year":"2024","unstructured":"Schein J, Cloutier M, Gauthier-Loiselle M, et al. Treatment preferences of adult patients with attention-deficit\/hyperactivity disorder\u2014a discrete choice experiment. Patient Prefer Adherence. 2024;18:1651\u201364.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"1033_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40120-024-00681-y","volume":"14","author":"J Schein","year":"2025","unstructured":"Schein J, Cloutier M, Gauthier-Loiselle M, et al. Treatment preferences of physicians treating adult patients with attention-deficit\/hyperactivity disorder in the United States and Canada: a discrete choice experiment. Neurol Ther. 2025;14(1):193\u2013210.","journal-title":"Neurol Ther"},{"key":"1033_CR22","unstructured":"Schein J, Catillon M, Meng Y, et al. Treatment preferences of parents\/caregivers of pediatric patients with attention deficit\/hyperactivity disorder in the United States and Canada\u2014a discrete choice experiment. In: ASHP midyear clinical meeting. 2025 December 7\u201310, 2025."},{"issue":"1","key":"1033_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"F Reed Johnson","year":"2013","unstructured":"Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16(1):3\u201313.","journal-title":"Value Health"},{"issue":"4","key":"1033_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403\u201313.","journal-title":"Value Health"},{"issue":"10","key":"1033_CR25","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s40273-024-01431-6","volume":"42","author":"J Ride","year":"2024","unstructured":"Ride J, Goranitis I, Meng Y, et al. A reporting checklist for discrete choice experiments in health: the DIRECT checklist. Pharmacoeconomics. 2024;42(10):1161\u201375.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"1033_CR26","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1176\/appi.ajp.159.11.1896","volume":"159","author":"D Michelson","year":"2002","unstructured":"Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159(11):1896\u2013901.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1033_CR27","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1542\/peds.2006-3695","volume":"121","author":"J Biederman","year":"2008","unstructured":"Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder. Pediatrics. 2008;121(1):e73\u201384.","journal-title":"Pediatrics"},{"issue":"3","key":"1033_CR28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0149-2918(07)80083-X","volume":"29","author":"J Biederman","year":"2007","unstructured":"Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit\/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29(3):450\u201363.","journal-title":"Clin Ther"},{"key":"1033_CR29","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40263-017-0468-2","volume":"31","author":"JH Newcorn","year":"2017","unstructured":"Newcorn JH, Nagy P, Childress AC, et al. Randomized, double-blind, placebo-controlled acute comparator trials of lisdexamfetamine and extended-release methylphenidate in adolescents with attention-deficit\/hyperactivity disorder. CNS Drugs. 2017;31:999\u20131014.","journal-title":"CNS Drugs"},{"issue":"6","key":"1033_CR30","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1089\/cap.2017.0084","volume":"27","author":"SR Pliszka","year":"2017","unstructured":"Pliszka SR, Wilens TE, Bostrom S, et al. Efficacy and safety of HLD200, delayed-release and extended-release methylphenidate, in children with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(6):474\u201382.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"1033_CR31","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.clinthera.2020.05.021","volume":"42","author":"A Nasser","year":"2020","unstructured":"Nasser A, Liranso T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit\/hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452\u201366.","journal-title":"Clin Ther"},{"issue":"4","key":"1033_CR32","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/JCP.0000000000001404","volume":"41","author":"A Nasser","year":"2021","unstructured":"Nasser A, Liranso T, Adewole T, et al. A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit\/hyperactivity disorder. J Clin Psychopharmacol. 2021;41(4):370.","journal-title":"J Clin Psychopharmacol"},{"key":"1033_CR33","unstructured":"Schein J, Catillon M, Lemyre A, et al., editors. Poster 120. Matching-adjusted indirect comparison of treatments for attention-deficit\/hyperactivity disorder in pediatric patients: a focus on short-term outcomes. In: Psych congress 2024 conference; Boston, MA, USA."},{"key":"1033_CR34","volume-title":"ADHD rating scale-IV: checklists, norms, and clinical interpretation.","author":"GJ DuPaul","year":"1998","unstructured":"DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD rating scale-IV: checklists, norms, and clinical interpretation. New York: Guilford Press; 1998."},{"key":"1033_CR35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4337\/9781800375635.00013","volume-title":"Handbook of Choice Modelling, chapter 7","author":"M Bliemer","year":"2024","unstructured":"Bliemer M, Rose J. Designing and conducting stated choice experiments. In: Hess S, Daly A, editors. Handbook of Choice Modelling, chapter 7: Edward Elgar Publishing; 2024. pp. 172\u2013205."},{"issue":"3","key":"1033_CR36","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00787-024-02538-z","volume":"34","author":"M Ferrin","year":"2025","unstructured":"Ferrin M, Hage A, Swanson J, et al. Medication adherence and persistence in children and adolescents with attention deficit hyperactivity disorder (ADHD): a systematic review and qualitative update. Eur Child Adolesc Psychiatry. 2025;34(3):867\u201382.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"1033_CR37","first-page":"1543","volume":"10","author":"K Gajria","year":"2014","unstructured":"Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit\/hyperactivity disorder\u2014a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543\u201369.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"12","key":"1033_CR38","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1007\/s12325-022-02329-5","volume":"39","author":"J Schein","year":"2022","unstructured":"Schein J, Cloutier M, Gauthier-Loiselle M, et al. Reasons for treatment changes in children and adolescents with attention-deficit\/hyperactivity disorder: a chart review study. Adv Ther. 2022;39(12):5487\u2013503.","journal-title":"Adv Ther"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01033-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01033-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01033-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:52:53Z","timestamp":1789494773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01033-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":38,"alternative-id":["1033"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01033-8","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"9 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jeff Schein is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. Marjolaine Gauthier-Loiselle, Yan Meng, Beatrice Libchaber, and Martin Cloutier, are employees of, and Maryaline Catillon and Francesca Lee are former employees of, Analysis Group ULC\/Inc., a consulting company that has provided paid consulting services to Otsuka Pharmaceutical Development & Commercialization, Inc. Ann Childress received research support from Aardvark, Allergan, Axsome, Emalex, Akili, Cingulate, Corium, Ironshore, Les Laboratoires Servier, Lumos, Neurocentria, Otsuka, Purdue, Adlon, Sunovion, Tris, KemPharm, and Supernus; was on the advisory board of Corium, Otsuka, Tris, and Supernus; received consulting fees from Aardvark, Alora, Axsome, Aytu, Cingulate, Corium, Lumos, Medison Pharma, Neurocentria, Noven, Otsuka, Sky, Tris, KemPharm, Supernus, and Tulex; received speaker fees from Takeda, Corium, Ironshore, Tris, and Supernus; and received writing support from Otsuka, Takeda, Corium, Ironshore, Purdue, and Tris.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eligible participants who were willing to participate in the study provided informed consent prior to responding to the survey. This study is exempt by Pearl IRB according to 45 CFR 46.104(d)(2) Tests, Surveys, Interviews 45 CFR 46.104(d)(2)(ii) on 11\/06\/2024.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}